Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

AKT1 E17K inhibitor ALTA2618

An orally bioavailable covalent inhibitor of the serine/threonine protein kinase AKT (protein kinase B; v-akt murine thymoma viral oncogene homolog 1) isoform 1 mutation AKT1 E17K, with potential antineoplastic activity. Upon oral administration, AKT1 E17K inhibitor ALTA2618 targets, allosterically binds to and inhibits AKT1 E17K. This may inhibit growth of and induce apoptosis in AKT1 E17K-driven cancers. AKT1 E17K, overexpressed in a variety of cancer cell types, drives cancer cell proliferation. By specifically targeting the E17K mutant variant, ALTA2618 may avoid the toxicities associated with wild-type (WT) AKT inhibition.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:AKT1 E17K-mutant inhibitor ALTA2618
mutant-selective AKT1 inhibitor ALTA2618
Code name:ALTA 2618
ALTA-2618
ALTA2618
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search